semaglutide compounding lawsuit news Drug compounders sue FDA over declaration ending Wegovy shortage Ozempic® Lawsuit | July 2026

It remains an investigational compound moving through Eli Lillys Phase 3 TRIUMPH clinical program

The table lists only three strengths for the branded pen and stops short of the highest strength the product is actually available in, so it understates the range

The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy

Weight loss and all three pathways may contribute to this result

This is one reason why highly concentrated solutions are impractical for lower doses

Fatigue during the initial titration phases is commonly reported across all incretin therapies